Unveiling the potential therapeutic role of nifuroxazide and liraglutide combination in mitigating LPS-induced acute lung injury through modulation of AT1R/JAK-2/STAT-3 by ACE2/ Ang1‐7/MasR signaling in male albino rats: in vivo and in silico study
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115261 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Amira Karam Khalifa und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Pharmacology, Faculty of Medicine, Cairo University, El- Manial, Cairo 11562, Egypt; Department of Medical Pharmacology, Facult…. Hauptthemen laut MEDLINE: Acute Lung Injury, Nitrofurans. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 89 Literaturangaben. Gefördert von: King Khalid University, King Khalid University Deanship of Scientific Research.
Abstract (Originalsprache)
The current study investigated the possible therapeutic role of a combination of liraglutide and nifuroxazide in ameliorating the JAK2/STAT3/NFĸB signaling pathway by augmenting the counter-regulatory ACE2/Ang1-7/MAS receptor axis of the renin angiotensin system (RAS). This therapeutic potential was further verified through molecular dynamic simulation studies. Seventy-five male Wistar albino rats were randomly allocated into 5 groups. The groups included normal control, LPS-induced ALI, ALI + NIF treated group, ALI + LIR-treated group, and ALI + LIR + NIF-treated group.The study revealed the promising therapeutic role of the liraglutide and nifuroxazide combination in significantly improving 7-day survival rates, ameliorating metabolic acidosis, and dampening the inflammatory response (IL-6, TNFα, iNOS, MPO, IL-1β) in bronchoalveolar lavage fluid (BALF). This was supported by the effective alleviation of pulmonary leakage, as evidenced by a remarkable decrease in wet lung weight/body weight ratio and wet/dry lung ratio. Additionally, the combination restored the redox balance by enhancing levels of SOD, catalase, and GSH. The combination regimen also improved the inflammatory score in histopathological examination, increased Nrf2 expression, and reduced iNOS immunoreactivity. These effects were attributed to the downregulation of total and phosphorylated protein expression of JAK2/STAT3/NFβB, and the upregulation of mRNA expression of ACE2 receptor, MAS receptors, and pulmonary lung surfactant B. Our study, which combined molecular dynamic simulation and experimental validation, provides a comprehensive perspective on managing septic acute lung injury, positioning the liraglutide and nifuroxazide combination regimen as a promising candidate for the management of septic acute lung injury (S-ALI).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Pharmacology, Faculty of Medicine, Cairo University, El- Manial, Cairo 11562, Egypt; Department of Medical Pharmacology, Faculty of Medicine, Nahda University, Beni Suef 62521, Egypt. Electronic ad…
- Department of Medical Pharmacology, Faculty of Medicine, Cairo University, El- Manial, Cairo 11562, Egypt. Electronic address: Wala2osman@cu.edu.eg.
- Department of Pathology, Faculty of Medicine, Cairo University, El- Manial, Cairo 11562, Egypt. Electronic address: ahmed.naeem@kasralainy.edu.eg.
- Department of Physiology(,) Faculty of Medicine, Cairo University, El Manial, Cairo 11562, Egypt. Electronic address: nagwa.m.abdullah@kasralainy.edu.eg.
- Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Cairo University, El- Manial, Cairo, Egypt; Department Basic Medical Science, Faculty of Medicine, King Salman International University, Sou…
- Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Cairo University, El- Manial, Cairo, Egypt. Electronic address: sara_kadry@kasralainy.edu.eg.
Förderung
- King Khalid University
- King Khalid University Deanship of Scientific Research
Zitieren
APA
Khalifa, A. K., Osman, W. A., Eesa, A. N., Ramadan, N. M., Abdelkader, A., Abdallah, S. S. K., Aboulhoda, B. E., Al-Shahed, F. A. N., Alghamdi, M. A., Elrashedy, A. A., Elshaer, M. M. A., Saber, S., Mahmoud, A. K., Ashraf, T., & Matter, L. M. (2025). Unveiling the potential therapeutic role of nifuroxazide and liraglutide combination in mitigating LPS-induced acute lung injury through modulation of AT1R/JAK-2/STAT-3 by ACE2/ Ang1‐7/MasR signaling in male albino rats: in vivo and in silico study. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115261
Vancouver
Khalifa AK, Osman WA, Eesa AN, Ramadan NM, Abdelkader A, Abdallah SSK, et al. Unveiling the potential therapeutic role of nifuroxazide and liraglutide combination in mitigating LPS-induced acute lung injury through modulation of AT1R/JAK-2/STAT-3 by ACE2/ Ang1‐7/MasR signaling in male albino rats: in vivo and in silico study. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115261
BibTeX
@article{Khalifa2025,
author = {Khalifa, Amira Karam and Osman, Walla''a A and Eesa, Ahmed Naeem and Ramadan, Nagwa Mahmoud and Abdelkader, Abeer and Abdallah, Sara Sayed Kadry and Aboulhoda, Basma Emad and Al-Shahed, Fatma Al-Zahraa Nabil and Alghamdi, Mansour A and Elrashedy, Ahmed A and Elshaer, Mohamed Mahmoud Abdelrahim and Saber, Sameh and Mahmoud, Alaa Karam and Ashraf, Taha and Matter, Lamiaa Mohammed},
title = {Unveiling the potential therapeutic role of nifuroxazide and liraglutide combination in mitigating LPS-induced acute lung injury through modulation of AT1R/JAK-2/STAT-3 by ACE2/ Ang1‐7/MasR signaling in male albino rats: in vivo and in silico study},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115261}
}
EUVIMED